🇺🇸 FDA
Patent

US 11939377

Affinity matured CD22-specific monoclonal antibody and uses thereof

granted A61KA61K2039/505A61K2039/804

Quick answer

US patent 11939377 (Affinity matured CD22-specific monoclonal antibody and uses thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
35
CPC classes
A61K, A61K2039/505, A61K2039/804, A61K2239/31, A61K2239/38